title: Treatment of Nonmetastatic Castration-Resistant Prostate Cancer.
abstract: Patients with nonmetastatic castration-resistant prostate cancer (CRPC) are a heterogeneous population with regard to risk of progression to metastatic disease. Treatment selection for nonmetastatic CRPC must balance the risk of disease progression with the side effects of available therapies. Several medication classes are available for use in treating these patients, and other newer agents are under active clinical trial investigation. Here we review current therapies for nonmetastatic CRPC and discuss the recently completed and ongoing trials for this emerging disease state.
authors.forename: Jia
authors.initials: J
authors.lastname: Luo
authors.forename: Tomasz M
authors.initials: TM
authors.lastname: Beer
authors.forename: Julie N
authors.initials: JN
authors.lastname: Graff
mesh_terms: D000726:Androgen Antagonists / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D006801:Humans; D008297:Male; D017430:Prostate-Specific Antigen / Q000097:blood; D064129:Prostatic Neoplasms, Castration-Resistant / Q000188:drug therapy*
chemical_list: D000726:Androgen Antagonists; D017430:Prostate-Specific Antigen